Morgan Stanley Maintains Overweight on CME Group, Raises Price Target to $337

Benzinga Newsdesk www.benzinga.com Positive 76.3%

Neg 0% Neu 0% Pos 76.3%

Morgan Stanley analyst Michael Cyprys maintains CME Group (NASDAQ:CME) with a Overweight and raises the price target from $330 to $337.